ABVC BioPharma, Inc. (ABVC)
NASDAQ:ABVC
Want to see ABVC full AI Analyst Report?
ABVC Stock Chart & Stats
$2.10
-$0.06(-10.00%)
At close: 4:00 PM EST
$2.10
-$0.06(-10.00%)
Day’s Range― - ―
52-Week Range$0.88 - $5.48
Previous CloseN/A
Volume151.09K
Average Volume (3M)95.05K
Market Cap
$27.98M
Enterprise Value$18.73M
Total Cash (Recent Filing)$745.83K
Total Debt (Recent Filing)$3.47M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding25,440,407
10 Day Avg. Volume116,541
30 Day Avg. Volume95,045
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)4.46
Price to Sales (P/S)62.24
P/FCF Ratio-16.56
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit32.19
Enterprise Value/Ebitda-3.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.3
Revenue Forecast (FY)$35.28M
Bulls Say, Bears Say
Bulls Say
Improved LeverageMaterial 2025 leverage improvement reduces near-term refinancing pressure and increases financial flexibility. A lower debt-to-equity ratio gives management more room to fund clinical programs or negotiate licensing deals without immediate debt strain, improving runway and partner confidence over months.
High Gross MarginsNear-100% gross margins indicate the company’s products or licensing revenues (if realized) would be highly scalable and capital-light at the cost-of-goods level. That structural margin profile supports high incremental profitability once fixed R&D and SG&A are covered or shifted to partners.
Pipeline Monetization ModelA focused out-licensing/partnering model reduces commercialization risk and capital intensity versus full commercialization. Structurally, this provides optionality to monetize assets via upfront/milestone/royalty streams and lets the company capture value while limiting ongoing commercial spend over the medium term.
Bears Say
Weak Cash GenerationPersistent inability to generate operating cash creates ongoing dependence on external financing. That elevates dilution and execution risk for multi-year clinical programs; funding uncertainty can delay trials, reduce bargaining power in partner deals, and pressure continuity of development efforts.
Deep LossesSevere recurring operating losses erode shareholder equity and limit strategic options. Over several quarters this weak profitability constrains reinvestment into R&D without fresh capital, weakens negotiating leverage with partners, and increases the chance management must prioritize financing over value-maximizing development.
Tiny, Volatile Revenue BaseA small, inconsistent revenue stream undermines the company’s ability to cover fixed SG&A and R&D. This structural instability makes cash flow planning difficult, heightens fundraising needs, and reduces credibility with potential licensees who prefer partners with stable or predictable revenues.
ABVC BioPharma News
ABVC FAQ
What was ABVC BioPharma, Inc.’s price range in the past 12 months?
ABVC BioPharma, Inc. lowest stock price was $0.88 and its highest was $5.48 in the past 12 months.
What is ABVC BioPharma, Inc.’s market cap?
ABVC BioPharma, Inc.’s market cap is $27.98M.
When is ABVC BioPharma, Inc.’s upcoming earnings report date?
ABVC BioPharma, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 193 days.
How were ABVC BioPharma, Inc.’s earnings last quarter?
ABVC BioPharma, Inc. released its earnings results on Mar 27, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.11.
Is ABVC BioPharma, Inc. overvalued?
According to Wall Street analysts ABVC BioPharma, Inc.’s price is currently Overvalued.
Does ABVC BioPharma, Inc. pay dividends?
ABVC BioPharma, Inc. does not currently pay dividends.
What is ABVC BioPharma, Inc.’s EPS estimate?
ABVC BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABVC BioPharma, Inc. have?
ABVC BioPharma, Inc. has 25,440,407 shares outstanding.
What happened to ABVC BioPharma, Inc.’s price movement after its last earnings report?
ABVC BioPharma, Inc. reported an EPS of -$0.11 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.66%.
Which hedge fund is a major shareholder of ABVC BioPharma, Inc.?
Currently, no hedge funds are holding shares in ABVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Technical Analysis
CervoMed
―
MindWalk Holdings
―
Jasper Therapeutics
―
MiNK Therapeutics
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
―
Insiders
1.43% Mutual Funds
0.05% Other Institutional Investors
97.78% Public Companies and
Individual Investors